Highest-materiality recent filing
Ginkgo Bioworks Q1 revenue $19M (-49% YoY); narrows net loss; cash burn guidance reaffirmed
Revenue $19M, down 49% YoY; prior year included $7M non-cash deferred revenue release; adjusted EBITDA -$42M.
Ginkgo completes sale of Biosecurity segment to Tower Biosecurity, retains 20% stake
On April 3, 2026, Ginkgo contributed all Biosecurity equity to Tower Biosecurity (Perimeter Systems) for ~20% of buyer's fully diluted shares.
Ginkgo Bioworks sells Biosecurity segment to Tower Biosecurity for 20% stake
Ginkgo contributes all equity of Ginkgo Biosecurity, LLC (its Biosecurity segment) to Tower Biosecurity.
Q4 2025 total revenue $33M, down 24% YoY; Cell Engineering $26M (-26%), Biosecurity $7M (-22%).
Ginkgo Q3 revenue $39M (-56% YoY); net loss $81M; reaffirms FY guide $167-187M
Total revenue $39M, down 56% YoY; prior year had $45M non-cash deferred revenue; ex that, down 11%.
Ginkgo Q2 2025 revenue $50M, net loss $60M; achieves $250M cost savings goal ahead of schedule
Total revenue $50M, down from $56M YoY; Cell Engineering rev up 8% to $39M; Biosecurity down to $10M.
Ginkgo CFO Dmytruk to resign May 30; CAO Coen appointed CFO
Mark Dmytruk resigns as CFO, effective May 30, 2025, to accept a position at another organization.
Mark Dmytruk, the Company’s Chief Financial Officer and principal financial officer, gave notice on May 19, 2025 of his intention to resign from these roles at the Company on May 30, 2025 to accept a position at another organization
Steven Coen, CPA, the Company’s Chief Accounting Officer, will become Chief Financial Officer, principal financial officer and principal accounting officer, effective upon Mr. Dmytruk’s resignation
Max materiality 0.75 · Median 0.65 · Most common event earnings